SEC Form 3 · accession 0002154450-26-000002
ADARx Pharmaceuticals, Inc. · ADRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alan Robert MacLeod
Officer — Chief Scientific Officer
Period of report
Sep 24, 2026
Accepted (ET)
Sep 24, 2026 · 6:37 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001802369
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $3.26 | holding | — | — | — | — | Feb 25, 2033 | Common Stock | 513,401 | — | D |
| Employee Stock Option (right to buy)F2 | $5.84 | holding | — | — | — | — | Jan 16, 2034 | Common Stock | 42,673 | — | D |
| Employee Stock Option (right to buy)F3 | $7.05 | holding | — | — | — | — | Feb 11, 2035 | Common Stock | 42,673 | — | D |
| Employee Stock Option (right to buy)F4 | $6.31 | holding | — | — | — | — | Jan 27, 2036 | Common Stock | 68,276 | — | D |
Explanation of responses
- F1Granted to the Reporting Person on February 26, 2023. 1/4 of the total number of shares vested and became exercisable on January 3, 2024 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- F2Granted to the Reporting Person on January 17, 2024. 1/4 of the total number of shares vested and became exercisable on January 1, 2025 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- F3Granted to the Reporting Person on February 12, 2025. 1/4 of the total number of shares vested and became exercisable on January 1, 2026 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- F4Granted to the Reporting Person on January 28, 2026. 1/4 of the total number of shares vest and become exercisable on January 1, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Remarks
Exhibit 24 - Power of Attorney